Project Alexander: Boehringer Ingelheim

As part of the EU FP7 Project Alexander, we investigated “Compound X” for Boehringer Ingelheim. This was a compound that had been taken into animal testing because of promising in vitro data. However the compound did not perform as was expected, and no therapeutic effects were seen.

With our systems we were able to show that the compound was not absorbed in the model system, and that the nanoparticle delivery system did not improve absorption (Figure 1). This demonstrates the value of pre-screening in the absorptive model before testing potential compounds and formulations in animals – and the related cost implications.

Figure 1 – Absorption of “Compound X” alone or in a nanoparticle delivery system through the epithelial model, as compared to an unimpeded absorption profile.

Let’s talk

Want to talk to us?

We’re a team of scientists who are excited about unique ideas and want to help our customers do great things.

Aelius Biotech:

Contact Us:


+44 (0)191 208 7443



The Biosphere Draymans Way, Newcastle Helix, Newcastle Upon Tyne, England, NE4 5BX

Work Enquiries:

Interested in working with us?
We use cookies to give you the best experience.